Heron Therapeutics (HRTX) Convertible Debt: 2011-2025
Historic Convertible Debt for Heron Therapeutics (HRTX) over the last 4 years, with Sep 2025 value amounting to $32.2 million.
- Heron Therapeutics' Convertible Debt fell 78.50% to $32.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.2 million, marking a year-over-year decrease of 78.50%. This contributed to the annual value of $149.7 million for FY2024, which is 0.14% up from last year.
- Per Heron Therapeutics' latest filing, its Convertible Debt stood at $32.2 million for Q3 2025, which was down 78.51% from $149.8 million recorded in Q1 2025.
- Heron Therapeutics' Convertible Debt's 5-year high stood at $149.8 million during Q1 2025, with a 5-year trough of $32.2 million in Q3 2025.
- In the last 3 years, Heron Therapeutics' Convertible Debt had a median value of $149.5 million in 2023 and averaged $137.8 million.
- Data for Heron Therapeutics' Convertible Debt shows a peak YoY increase of 0.14% (in 2025) and a maximum YoY decrease of 78.50% (in 2025) over the last 5 years.
- Heron Therapeutics' Convertible Debt (Quarterly) stood at $149.1 million in 2021, then increased by 0.14% to $149.3 million in 2022, then rose by 0.14% to $149.5 million in 2023, then climbed by 0.14% to $149.7 million in 2024, then crashed by 78.50% to $32.2 million in 2025.
- Its Convertible Debt stands at $32.2 million for Q3 2025, versus $149.8 million for Q1 2025 and $149.7 million for Q4 2024.